Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER

Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER
Recruiting
18 years - 99 years
All
Phase 2
2 participants needed
1 Location

Brief description of study

This research study is to find out if the study drug eltrombopag also known as Revolade/Promacta can help those who have Immune Thrombocytopenia (ITP.)  The study will determine if subjects are able to stop eltrombopag treatment while maintaining acceptable platelet levels after their disease has become resistant to treatment or has a reoccurrence of symptoms after initial treatment with steroids. This study will enroll subjects who are at least 18 years old, have refractory ITP and have failed first line treatments.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Immune Thrombocytopenia
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 833549

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Race
Select race of your choice
Ethnicity
Select ethinicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center